Who founded Axon Therapies?

Axon Therapies was founded by Howard R. Levin, Mark Gelfand in 2014.

Who are Axon Therapies's investors?

Axon Therapies's investors include Deerfield Management Company, SV Health Investors.

How much funding has Axon Therapies raised?

Axon Therapies has disclosed $10.8M raised across 3 rounds.

Where is Axon Therapies headquartered?

Axon Therapies is headquartered in New York, US.

Axon Therapies

New York, US · Founded 2014 · Delaware corporation · 2 known investors

Axon Therapies develops the SAVM procedure, an implant-free catheter-based ablation therapy that targets the right greater splanchnic nerve to reduce overactive sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF). Its Axon Ablation Catheter is used in an outpatient procedure to block nerve signals and normalize volume balance.

Healthtech Medical Devices

Founders & leadership

Axon Therapies was founded in 2014 by Howard R. Levin and Mark Gelfand.

Howard R. LevinCo-founder

Mark GelfandCo-founder

Mitchell S. BloomNamed on SEC filing

Board

Paul LaViolette inBoard directorManaging Partner at SV Health Investors

Investors · 2

Deerfield Management CompanyreportedNew Yorkvia Andrew ElBardissi · board

SV Health InvestorsreportedBoston · $1M – $20Mvia Paul LaViolette · board

Reported raises · per SEC filings

Form D private placements

$10.8M disclosed across 3 rounds · 2016–2019

▶$7.5MraisedFeb 2019 · 10 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Mitchell S. BloomExecutive Officer
Steven HochbergDirector
Paul LaVioletteDirector
Mark GelfandExecutive Officer, Director
Howard R. LevinExecutive Officer, Director
Imran EbaDirector
Andrew ElBardissiDirector

Offering amount: $15M
Amount sold: $7.5M
First sale: Jan 2019
Incorporated: Corporation, Delaware, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.3MraisedJun 2017 · 7 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Mark GelfandExecutive Officer
Howard R. LevinExecutive Officer, Director
Mitchell S. BloomExecutive Officer
Paul LaVioletteDirector

Offering amount: $2M
Amount sold: $1.3M
First sale: Jun 2017
Incorporated: Corporation, Delaware, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2MraisedApr 2016 · 1 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Paul LaVioletteDirector
Howard R. LevinExecutive Officer, Director
Mark GelfandExecutive Officer
Mitchell S. BloomExecutive Officer

Offering amount: $2M
Amount sold: $2M
First sale: Apr 2016
Incorporated: Corporation, Delaware, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Boston Scientific6 shared keywordsBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.

Companies competing with Axon Therapies for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Axon Therapies do?: Axon Therapies develops the SAVM procedure, an implant-free catheter-based ablation therapy that targets the right greater splanchnic nerve to reduce overactive sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF). Its Axon Ablation Catheter is used in an outpatient procedure to block nerve signals and normalize volume balance.
Who founded Axon Therapies?: Axon Therapies was founded by Howard R. Levin, Mark Gelfand in 2014.
Who are Axon Therapies's investors?: Axon Therapies's investors include Deerfield Management Company, SV Health Investors.
How much funding has Axon Therapies raised?: Axon Therapies has disclosed $10.8M raised across 3 rounds.
Where is Axon Therapies headquartered?: Axon Therapies is headquartered in New York, US.